Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance

SUMMARY The increased use of antibacterial and antifungal agents in recent years has resulted in the development of resistance to these drugs. The significant clinical implication of resistance has led to heightened interest in the study of antimicrobial resistance from different angles. Areas addressed include mechanisms underlying this resistance, improved methods to detect resistance when it occurs, alternate options for the treatment of infections caused by resistant organisms, and strategies to prevent and control the emergence and spread of resistance. In this review, the mode of action of antifungals and their mechanisms of resistance are discussed. Additionally, an attempt is made to discuss the correlation between fungal and bacterial resistance. Antifungals can be grouped into three classes based on their site of action: azoles, which inhibit the synthesis of ergosterol (the main fungal sterol); polyenes, which interact with fungal membrane sterols physicochemically; and 5-fluorocytosine, which inhibits macromolecular synthesis. Many different types of mechanisms contribute to the development of resistance to antifungals. These mechanisms include alteration in drug target, alteration in sterol biosynthesis, reduction in the intercellular concentration of target enzyme, and overexpression of the antifungal drug target. Although the comparison between the mechanisms of resistance to antifungals and antibacterials is necessarily limited by several factors defined in the review, a correlation between the two exists. For example, modification of enzymes which serve as targets for antimicrobial action and the involvement of membrane pumps in the extrusion of drugs are well characterized in both the eukaryotic and prokaryotic cells.

[1]  Herbert E. Carter,et al.  Protection of fungi against polyene antibiotics by sterols. , 1958, Science.

[2]  R. Safferman,et al.  MECHANISM OF PROTECTION BY STEROLS AGAINST POLYENE ANTIBIOTICS , 1960, Journal of bacteriology.

[3]  W. Zygmunt,et al.  Steroid interference with antifungal activity of polyene antibiotics. , 1966, Applied microbiology.

[4]  R. Jund,et al.  Genetic and Physiological Aspects of Resistance to 5-Fluoropyrimidines in Saccharomyces cerevisiae , 1970, Journal of bacteriology.

[5]  R. Moellering,et al.  Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. , 1971, The Journal of clinical investigation.

[6]  R. Moellering,et al.  II. EFFECT OF VARIOUS ANTIBIOTICS ON THE UPTAKE OF 4C-LABELED STREPTOMYCIN BY ENTEROCOCCI , 1971 .

[7]  H. I. Winner,et al.  The development of resistance by candida species to polyene antibiotics in vitro. , 1971, Journal of medical microbiology.

[8]  G. Medoff,et al.  Synergistic Action of Amphotericin B and 5-Fluorocytosine Against Yeast-Like Organisms 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  S. Normark,et al.  In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata , 1972, Antimicrobial Agents and Chemotherapy.

[10]  J. Hamilton-miller Physiological properties of mutagen-induced variants of Candida albicans resistant to polyene antibiotics. , 1972, Journal of medical microbiology.

[11]  A. Norman,et al.  Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. , 1972, The Journal of biological chemistry.

[12]  M. Kleinschmidt,et al.  Effect of filipin on liposomes prepared with different types of steroids. , 1972, Plant physiology.

[13]  A. Norman,et al.  Studies on the biological properties of polyene antibiotics: comparison of other polyenes with filipin in their ability to interact specifically with sterol. , 1972, Biochimica et biophysica acta.

[14]  R. A. Woods,et al.  Polyene resistance and the isolation of sterol mutants in Saccharomyces cerevisiae. , 1972, Journal of general microbiology.

[15]  J. Hamilton-miller Chemistry and Biology of the Polyene Macrolide Antibiotics , 1973, Bacteriological reviews.

[16]  D. Feingold,et al.  Polyene antibiotic action on lecithin liposomes: effect of cholesterol and fatty acyl chains. , 1973, Biochemical and biophysical research communications.

[17]  Chemistry and biology of the polyene macrolide antibiotics. , 1973, Bacteriological reviews.

[18]  J. Hamilton-miller Chemistry and biology of the polyene macrolide antibiotics , 1973, Bacteriological reviews.

[19]  E. Grunberg,et al.  Chemotherapeutic Activity of 5-Fluorocytosine and Amphotericin B Against Candida albicans in Mice , 1973, Antimicrobial Agents and Chemotherapy.

[20]  A. Oehlschlager,et al.  Sterol biosynthesis in antibiotic-resistant yeast: nystatin. , 1974, Archives of biochemistry and biophysics.

[21]  B. de Kruijff,et al.  Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. 3. Molecular structure of the polyene antibiotic-cholesterol complexes. , 1974, Biochimica et biophysica acta.

[22]  H. Kropp,et al.  THE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN) , 1974, Annals of the New York Academy of Sciences.

[23]  R. Holz THE EFFECTS OF THE POLYENE ANTIBIOTICS NYSTATIN AND AMPHOTERICIN B ON THIN LIPID MEMBRANES , 1974, Annals of the New York Academy of Sciences.

[24]  J. Lanyi,et al.  Lipid interactions in membranes of extremely halophilic bacteria. II. Modification of the bilayer structure by squalene. , 1974, Biochemistry.

[25]  E. Brockman Mechanisms of Resistance , 1974 .

[26]  A. Johnson,et al.  Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth. , 1975, Journal of general microbiology.

[27]  A. Polak,et al.  Mode of action of 5-fluorocytosine and mechanisms of resistance. , 1975, Chemotherapy.

[28]  G. Sarosi,et al.  Synergistic action of amphotericin B and rifampin against Candida species. , 1976, The Journal of infectious diseases.

[29]  P. Traxler,et al.  Papulacandins, a new family of antibiotics with antifungal activity, I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D and E. , 1977, The Journal of antibiotics.

[30]  Papulacandins a new family of antibiotics with anti fungal activity part 1 fermentation isolation chemical and biological characterization of papulacandins , 1977 .

[31]  T. Saito,et al.  On the mode of action of a new antifungal antibiotic, aculeacin A: inhibition of cell wall synthesis in Saccharomyces cerevisiae. , 1977, The Journal of antibiotics.

[32]  J. E. Bennett,et al.  Mode of action of 5-fluorocytosine. , 1978, Biochemical pharmacology.

[33]  H. van den Bossche,et al.  Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. , 1978, Chemico-biological interactions.

[34]  J. Dubremetz,et al.  Ultrastructure of the cell wall of Candida albicans blastospores: study of its constitutive layers by the use of a cytochemical technique revealing polysaccharides. , 1978, Annales de microbiologie.

[35]  D. Kerridge,et al.  Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. , 1979, Journal of general microbiology.

[36]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[37]  W. Merz,et al.  Incidence of polyene-resistant yeasts recovered from clinical specimens , 1980, Antimicrobial Agents and Chemotherapy.

[38]  D. Lloyd,et al.  The Eukaryotic Microbial Cell , 1981 .

[39]  D. Kerridge,et al.  Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. , 1981, Sabouraudia.

[40]  D. Feingold,et al.  Mechanisms of action of the antimycotic imidazoles. , 1981, The Journal of investigative dermatology.

[41]  G. Sarosi,et al.  Combined action of amphotericin B and 5-fluorocytosine on pathogenic yeasts susceptible to either drug alone. , 1981, Chemotherapy.

[42]  D. Stevens,et al.  Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States , 1982, Antimicrobial Agents and Chemotherapy.

[43]  R. R. Robinson,et al.  Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. , 1982, Kidney international.

[44]  E. S. Beneke,et al.  Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates , 1982, Antimicrobial Agents and Chemotherapy.

[45]  A. Polak,et al.  Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. , 1982, Chemotherapy.

[46]  A. Chopra,et al.  Lipids of pathogenic fungi. , 1983, Progress in lipid research.

[47]  W. Beggs Comparison of miconazole- and ketoconazole-induced release of K+ from Candida species. , 1983, The Journal of antimicrobial chemotherapy.

[48]  C. Molloy,et al.  An analysis of the metabolism and cell wall composition of Candida albicans during germ-tube formation. , 1983, Canadian journal of microbiology.

[49]  H. van den Bossche,et al.  Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. , 1983, Biochemical Society transactions.

[50]  D. Kerridge,et al.  Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans , 1984, Antimicrobial Agents and Chemotherapy.

[51]  N. Ryder,et al.  Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans , 1984, Antimicrobial Agents and Chemotherapy.

[52]  L. J. Nisbet,et al.  The effect of aculeacin A and papulacandin B on morphology and cell wall ultrastructure in Candida albicans. , 1984, Canadian journal of microbiology.

[53]  R. Prasad,et al.  Effect of phospholipid enrichment on nystatin action: differences in antibiotic sensitivity between in vivo and in vitro conditions. , 1985, Microbios.

[54]  R. Prasad,et al.  Phospholipid enrichment of Saccharomyces cerevisiae and its effect on polyene sensitivity. , 1985, Canadian journal of microbiology.

[55]  G. Medoff,et al.  Sensitivity of Candida albicans to amphotericin B administered as single or fractionated doses , 1986, Antimicrobial Agents and Chemotherapy.

[56]  J. V. van Cutsem,et al.  Azole resistance in Candida albicans. , 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[57]  N. Russell,et al.  The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. , 1987, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[58]  R. Juliano,et al.  Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. , 1987, Molecular pharmacology.

[59]  W. Whelan The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. , 1987, Critical reviews in microbiology.

[60]  L. Liu,et al.  In‐vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue disposition of the drug in mice , 1987, The Journal of pharmacy and pharmacology.

[61]  L. Frankel,et al.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Barber,et al.  Fatal disseminated cryptococcosis following intraocular involvement. , 1988, The British journal of ophthalmology.

[63]  P. Gopal,et al.  Evidence for a glycosidic linkage between chitin and glucan in the cell wall of Candida albicans. , 1988, Journal of general microbiology.

[64]  R F Woolson,et al.  Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.

[65]  V. Wiebe,et al.  Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. , 1988, Reviews of infectious diseases.

[66]  C. Bizet,et al.  In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. , 1989, The Journal of infectious diseases.

[67]  G. Khuller,et al.  Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents. , 1989, Indian journal of biochemistry & biophysics.

[68]  E. Anaissie,et al.  Nosocomial fungal infections. Old problems and new challenges. , 1989, Infectious disease clinics of North America.

[69]  David John Adams,et al.  Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. , 1990, The Biochemical journal.

[70]  S. Levy Starting life resistance-free. , 1990, The New England journal of medicine.

[71]  H. Gallis,et al.  Amphotericin B: 30 years of clinical experience. , 1990, Reviews of infectious diseases.

[72]  T. Walsh,et al.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis , 1991, Antimicrobial Agents and Chemotherapy.

[73]  G. Hunter,et al.  In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus , 1991, Antimicrobial Agents and Chemotherapy.

[74]  Mitchell L. Cohen Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era , 1992, Science.

[75]  J. Tkacz Glucan Biosynthesis in Fungi and its Inhibition , 1992 .

[76]  N. Georgopapadakou,et al.  Emerging Targets in Antibacterial and Antifungal Chemotherapy , 2012, Springer US.

[77]  D. Livermore Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.

[78]  J. Duval,et al.  Resistance of enterococci to aminoglycosides and glycopeptides. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  F. Odds,et al.  Characterization of an azole-resistant Candida glabrata isolate , 1992, Antimicrobial Agents and Chemotherapy.

[80]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[81]  S. Levy,et al.  Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli , 1993, Journal of bacteriology.

[82]  C. Roessner,et al.  Sequence of the Candida albicans erg7 gene. , 1993, Gene.

[83]  P. Marichal,et al.  Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans , 1993, Antimicrobial Agents and Chemotherapy.

[84]  D I Edwards,et al.  Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance. , 1993, The Journal of antimicrobial chemotherapy.

[85]  G. Kaatz,et al.  Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter , 1993, Antimicrobial Agents and Chemotherapy.

[86]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[87]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[88]  D I Edwards,et al.  Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. , 1993, The Journal of antimicrobial chemotherapy.

[89]  E. Anaissie,et al.  Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity , 1993, Infection and immunity.

[90]  R. Fromtling,et al.  Cutaneous antifungal agents : selected compounds in clinical practice and development , 1993 .

[91]  R. Hector,et al.  Compounds active against cell walls of medically important fungi , 1993, Clinical Microbiology Reviews.

[92]  N. Georgopapadakou,et al.  Human mycoses: drugs and targets for emerging pathogens. , 1994, Science.

[93]  S. Kelly,et al.  Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. , 1994, FEMS microbiology letters.

[94]  A. Casadevall,et al.  Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole , 1994, Antimicrobial Agents and Chemotherapy.

[95]  J. McCutchan,et al.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  D. Livermore,et al.  Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance , 1994, Antimicrobial Agents and Chemotherapy.

[97]  B. Spratt,et al.  Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics. , 1994, Trends in microbiology.

[98]  L. Gutmann,et al.  beta-lactamase inhibitors . beta-lactamase conferring resistance to coli producing TEM-1 derivatives or an OXA-1 Emergence of clinical isolates of Escherichia , 1994 .

[99]  M. Pfaller,et al.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  G. Satta,et al.  Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium , 1994, Antimicrobial Agents and Chemotherapy.

[101]  L. Samaranayake,et al.  Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. , 1994, Journal of medical microbiology.

[102]  K. Kuchler,et al.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.

[103]  J. Swartz,et al.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.

[104]  T. Kocagoz,et al.  Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance , 1995, Antimicrobial agents and chemotherapy.

[105]  S. Michaelis,et al.  Sequence comparison of yeast ATP-binding cassette proteins. , 1995, Cold Spring Harbor symposia on quantitative biology.

[106]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[107]  T. Parkinson,et al.  Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata , 1995, Antimicrobial agents and chemotherapy.

[108]  L. Gutmann,et al.  Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium , 1996, Journal of bacteriology.

[109]  J. Rex,et al.  Resistance to antifungal agents in the critical care setting: problems and perspectives. , 1996, New horizons.

[110]  N. Gow,et al.  Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance , 1996, Antimicrobial agents and chemotherapy.

[111]  T J Walsh,et al.  Antifungal agents: chemotherapeutic targets and immunologic strategies , 1996, Antimicrobial agents and chemotherapy.

[112]  Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice , 1996, Antimicrobial agents and chemotherapy.

[113]  H. Jenkinson Ins and Outs of Antimicrobial Resistance: Era of the Drug Pumps , 1996, Journal of dental research.

[114]  P. Courvalin,et al.  Glycopeptide resistance in enterococci. , 1996, Trends in microbiology.

[115]  R. Haubrich,et al.  Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[116]  D. Sanglard,et al.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors , 1996, Antimicrobial agents and chemotherapy.

[117]  D. Bryant,et al.  Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics , 1996, Journal of bacteriology.

[118]  T. C. White,et al.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus , 1997, Antimicrobial agents and chemotherapy.

[119]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[120]  Brian C. Baldwin,et al.  The Mutation T315A in Candida albicans Sterol 14α-Demethylase Causes Reduced Enzyme Activity and Fluconazole Resistance through Reduced Affinity* , 1997, The Journal of Biological Chemistry.

[121]  D. Landsman,et al.  New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[122]  M. Ghannoum,et al.  A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei , 1997, Antimicrobial agents and chemotherapy.

[123]  D. Gerding,et al.  Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance Guidelines for the Prevention of Antimicrobial Resistance in Hospitals , 1997, Infection Control & Hospital Epidemiology.

[124]  T. C. White,et al.  The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[125]  M. Ghannoum,et al.  Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.

[126]  C. Douglas,et al.  Lipopeptide inhibitors of fungal glucan synthase. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[127]  D. Gerding,et al.  Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. , 1997, Infection control and hospital epidemiology.

[128]  A. Espinel-Ingroff Clinical relevance of antifungal resistance. , 1997, Infectious disease clinics of North America.

[129]  M. Ghannoum,et al.  Mechanism of Fluconazole Resistance inCandida krusei , 1998, Antimicrobial Agents and Chemotherapy.

[130]  J. Graybill,et al.  Fluconazole versus Candida albicans: A Complex Relationship , 1998, Antimicrobial Agents and Chemotherapy.

[131]  P. Loiseau,et al.  Mechanism of Amphotericin B Resistance inLeishmania donovani Promastigotes , 1998, Antimicrobial Agents and Chemotherapy.

[132]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[133]  B. Kullberg,et al.  Guidelines for the prevention of antimicrobial resistance in hospitals. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[134]  J. Acar,et al.  Rapid emergence of resistance to cefepime during treatment. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[135]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[136]  M. Ghannoum,et al.  Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. , 1999, Journal of chemotherapy.

[137]  Effects of Cilofungin ( LYI 21019 ) on Carbohydrate and Sterol Composition of Candida albicans , .